stockchase picture

Compiling comments that experts make about stocks while on public TV.

Expert Index

List by First Name

List by Last Name

Gordon Reid , President and CEO

GoodReid Investment Counsel

Address
47 Colborne Street
Suite 400
Toronto, ON
M5E 1P8

Contact Info
Telephone: 416.364.0890
Toll Free: 1.888.466.3734
Fax: 416.364.1788
Email:


Date Signal Chart Symbol Company Opinion Price
2015-06-16 N/A Must be logged in to use chart A Commentary A Comment -- General Comments From an Expert

Economy. Federal reserve just started its two-day meeting and his guess is that they will raise rates. Thinks they are anxious to get going on it and send a message. A quarter-point or a half a point is not going to have a big monetary influence on the market. The suggestion that the Fed is ready to move and the economy is ready to absorb higher rates is very important to them, so he thinks they will go, but then probably take a bit of a break and talk the markets up a bit. On bonds, his guess is that the long end of the curve continues to be in the control of the bond market. The Fed, of course, has great control of the short end of the curve, and with their bond buying program has some influence on the long end of the curve through a quantitative easing program. The market itself is going to take a bit of control, understanding that we are into a bit of a stronger economy and the Fed will start to normalize the monetary policy.


Price:
$0.020
Subject:
US LARGE
Bias:
UNKNOWN
Owned:
_N/A
2015-06-16 N/A Must be logged in to use chart A Commentary A Comment -- General Comments From an Expert

Markets. Investors are kind of bearish from a sentiment standpoint, and that is a great and powerful contrarian indicator. We are seeing a good deal of negative sentiment which is positive for the market, certainly in the short-term. Technically we are in a bit of an oversold condition.


Price:
$0.020
Subject:
US LARGE
Bias:
UNKNOWN
Owned:
_N/A
2015-06-16 COMMENT Must be logged in to use chart AAPL-Q Apple

We are always encouraged by our stocks doing well, but the important thing is the underlying company and is it moving at the same rate of growth as the stock price. If it is, then we know that the metrics are basically staying the same or getting less expensive. This is a victim of its own success. The iPhone has been tremendously successful and is their high margin product. He would like to see a bigger pie and thinks we are seeing that as they are expanding their product base.


Price:
$127.600
Subject:
US LARGE
Bias:
UNKNOWN
Owned:
Yes
2015-06-16 COMMENT Must be logged in to use chart AIG-N American International Group

This came out of the 08-09 debacle as a new company, a property/casualty insurer. It has done well for him. Yield curve is starting to steepen, and for an insurer, that is a good thing. They make most of their money off their portfolio, which is almost entirely in bonds. There are some good things happening at this company.


Price:
$61.980
Subject:
US LARGE
Bias:
UNKNOWN
Owned:
Yes
2015-06-16 HOLD Must be logged in to use chart ANTM-N Anthem Inc

This is an insurer and insures about 40 million Americans. If you were going into this area he would go big because they have scale. The operating leverage of that kind of model is very, very positive. Trading at about 14X earnings.


Price:
$166.850
Subject:
US LARGE
Bias:
UNKNOWN
Owned:
Yes
2015-06-16 COMMENT Must be logged in to use chart BAC-N Bank of America

Thinks you will do well with this bank. The whole banking sector is going to be the beneficiary of the steepening yield curve. That allows banks to do the old-fashioned thing of borrowing short and lending long, at a spread. (See Top Picks.)


Price:
$17.550
Subject:
US LARGE
Bias:
UNKNOWN
Owned:
No
2015-06-16 DON'T BUY Must be logged in to use chart CELG-Q Celgene Corp

Trading at about 40X earnings. They have a couple of very good drugs, but have front ended drugs, with one drug representing about 65% of their total revenue.


Price:
$111.110
Subject:
US LARGE
Bias:
UNKNOWN
Owned:
Unknown
2015-06-16 COMMENT Must be logged in to use chart GILD-Q Gilead Sciences Inc.

A lot of people on the street like this stock, but his concern is that 55% of their revenue comes from 2 drugs, both in the hepatitis C area, and are a cure. There is competition, so from an investment standpoint when you design or invent something that cures a disease, your market obviously goes away. Also, when other companies come out with competitive products, they are not only going to eat into your market share, but are going to eat into your margins, because they are going to fight you on price. Price is a very big issue with this company’s drugs. If their pipeline is not successful in coming out with more breadth, they are going to be exposed to lower prices on their products, lower volumes, and ultimately a shrinking market. The risk is too high for him.


Price:
$119.070
Subject:
US LARGE
Bias:
UNKNOWN
Owned:
No
2015-06-16 COMMENT Must be logged in to use chart HON-N Honeywell International

This is one that he missed. It has done very, very well for investors. One of the premier industrials in the US.


Price:
$104.100
Subject:
US LARGE
Bias:
UNKNOWN
Owned:
No
2015-06-16 COMMENT Must be logged in to use chart JNJ-N Johnson & Johnson

Doing very well on the pharma side, but not as well on the medical device side. Their whole complex is having some difficulty with the US$, but are not alone there. When you look at the US$ and the effect it is having on companies and their results, you have to look at it as a transitory type of event. You are not going to have the same debilitating type of event quarter after quarter after quarter, unless the dollar continues to strengthen at the same rate. At this point, this company is just a little too pricey for him.


Price:
$98.360
Subject:
US LARGE
Bias:
UNKNOWN
Owned:
Unknown
2015-06-16 COMMENT Must be logged in to use chart JPM-N JP Morgan Chase & Co

Banks are going to be more sensitive to the effect of the bond market on long rates, rather than what the Fed does. This is a more senior bank and didn’t get hurt as much as the other banks during the 08-09 experience. Because of this, on a recovery you will probably see less of a recovery. Based on that, Bank of America (BAC-N) and Citigroup (C-N) would be better choices. (See Top Picks.)


Price:
$68.370
Subject:
US LARGE
Bias:
UNKNOWN
Owned:
Unknown
2015-06-16 DON'T BUY Must be logged in to use chart MCK-N McKesson Corp

In drug distribution, mostly generic, and has done a wonderful job. A lot of their growth has happened and the price ($234) reflects a great deal of optimism in the future. Growth is slowing somewhat, and is coming from different places as opposed to being organic growth, such as stock buybacks, reduced floats.


Price:
$234.440
Subject:
US LARGE
Bias:
UNKNOWN
Owned:
No
2015-06-16 COMMENT Must be logged in to use chart MRK-N Merck & Company

For many years he has tended to stay clear of the traditional pharmaceuticals that have primarily chemical-based compounds. Feels that from a financial standpoint they have a very stiff breeze in their face. The generic drug legislation in the US moves these drugs away from these companies and into the hands of generic operators. Basically the pharmas lose a lot of the revenue oomph that they are providing.


Price:
$57.710
Subject:
US LARGE
Bias:
UNKNOWN
Owned:
No
2015-06-16 DON'T BUY Must be logged in to use chart ORCL-N Oracle

Sold his holdings a few years ago because of slowing revenue growth. They were maintaining their earnings growth, but revenues were starting to slow. When looking at companies, EPS and Price to Earnings Ratios is what everybody wants to look at, but they can be deceiving. This is a good example where a company can grow its earnings by cutting expenses. Revenues are really the fuel of earnings.


Price:
$44.640
Subject:
US LARGE
Bias:
UNKNOWN
Owned:
No
2015-06-16 COMMENT Must be logged in to use chart RYL-N Ryland Group

This is up and down. The whole homebuilder area has been a very lumpy recovery. Still in the very early stages. In terms of household formations, we are still severely under the averages, let alone the peak of where we were in the boom times. There is a lot of room ahead and thinks we are in a very early stage for the whole group. This one is merging with Standard Pacific (SPF-N) and he is going to have to look at the combined group to see if he will continue to own it. He wants to be in the strongest in the sector.


Price:
$45.420
Subject:
US LARGE
Bias:
UNKNOWN
Owned:
Yes
Showing 1 to 15 of 1,544 entries
First Previous 1 2 3 4 5 Next Last

No Comments.


You must be logged in to comment.